Assessing Ocular Surface Changes After Changing Glaucoma Medications
Completed
- Conditions
- GlaucomaOcular Surface DiseaseMonotherapy With Xalatan From 1 to 18 Months
- Registration Number
- NCT00554411
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.
- Detailed Description
Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- on Xalatan monotherapy from 1 to 18 months
- 18 years of age or older
- has been diagnosed with ocular surface disease
Read More
Exclusion Criteria
- special populations such as children, pregnant females, prisoners, etc.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Signs and Symptoms of Ocular Surface Disease 6 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rocky Mountain Lions Eye Institute
🇺🇸Aurora, Colorado, United States